Connection
Allen Cohn to Caspase 3
This is a "connection" page, showing publications Allen Cohn has written about Caspase 3.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.023 |
|
|
|
-
Fuchs CS, Fakih M, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, Haddad V, Hsu CP, Sabin A, Saltz L. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer. 2013 Dec 15; 119(24):4290-8.
Score: 0.023